Phase 2 N=37 Neuropeptide Treatment for Hot Flushes During the Menopause
Menopausal Flushing
Primary: Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period — 19.35; 49.01 hot flushes — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=141 Flushing Reduction Associated With Nitrates
Menopausal Hot Flashes
Primary: Change From Baseline Hot Flash Frequency — -4.56; -4.02 Hot flashes per day — p=0.34
Phase 4 N=20 Understanding Experimentally Induced Hot Flushes
Hot Flashes
Primary: Percent Change in Objective Sleep Efficiency — -2.6; 4.2 percent change
Phase 2 N=356 Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
Menopausal and Female Climacteric States
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) and Number of Participants With Mild, Moderate and Severe AE — 54; 52; 45; 51 Participants
Phase 3 N=943 Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
Menopause · Vasomotor Symptoms
Primary: Change From Baseline in Average Daily Frequency of Vasomotor Symptoms (Frequency Score A) at Week 4 — -3.9; -5.6; -6.0; -6.0 Number of events — p=<0.01
Phase 3 N=150 Oxybutynin Chloride in Managing Hot Flashes
Breast Carcinoma · Ductal Breast Carcinoma In Situ · Hot Flashes
Primary: Average Change in Hot Flash Activity Score From Baseline to Week 7 for Low Dose Oxybutynin vs Placebo and for High Dose Oxybutynin vs Placebo — -16.9; -10.6; -5.7 score…
Phase 3 N=189 Progesterone for Perimenopausal Night Sweats
Hot Flushes · Night Sweats
Primary: Vasomotor Symptoms (VMS)/ VMS Score - at 12 Weeks — 5.5; 7.1 Units of Vasomotor Symptom Score
Phase 4 N=29 Impact of Hot Flashes on Sleep and Mood Disturbance
Menopause · Depression · Hot Flashes
Primary: Percent Change in Wake After Sleep Onset (WASO) — 62 percent change — p=0.007
Phase 3 N=945 Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
Postmenopausal Symptoms · Menopause · Vasomotor Symptoms
Primary: Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms (Frequency Score A) at Week 4 — 12.1; 12.2; 12.6; 12.3 Events per day — p=<0.01
Phase 3 N=501 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
Hot Flashes
Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.72; -5.53; -6.26 VMS per day — p=<0.001
N/A N=187 Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial
Hot Flashes
Primary: Hot Flash Frequency — 27.19; 68.26; 19.44; 62.32 hot flashes per week
Phase 3 N=527 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
Hot Flashes
Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.32; -5.19; -5.39 VMS per day — p=<0.001
N/A N=50 EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
Breast Carcinoma · Breast Ductal Carcinoma In Situ · Breast Lobular Carcinoma In Situ
Primary: Device Usage
Phase 2 N=356 A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
Menopause · Hot Flashes
Primary: Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 — -4.2; -6.1; -7.2; -7.0 VMS per…
N/A N=38 Reducing the Experience of Menopausal Symptoms Through Temperature
Hot Flashes · Menopause
Primary: Hot Flash Diary — 9 number of hot flashes per week
N/A N=36 Vilazodone for Menopausal Hot Flashes
Hot Flushes
Primary: Daily Diary Ratings of Frequency of Hot Flashes — 3.65; 4.71 number of hot flashes — p=0.05
Phase 1 N=103 Study of Erenumab (AMG 334) in Women With Hot Flashes
Vasomotor Symptoms; Hot Flashes
Primary: Ratio of Week 4 to Baseline Average Number of Daily Moderate to Severe Hot Flashes — 0.35; 0.38 ratio — p=0.723
Phase 2 N=169 Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients
Menopause
Primary: Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period) — 73.5; 69.5; 70.4; 67.9 Number of MSVS/2 weeks — p=0.5730
Phase 3 N=595 Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women
Hot Flashes
Primary: G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period…
Phase 3 N=559 Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.
Hot Flashes
Primary: Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 4 Weeks of Treatment — -7.0; -6.9; -5.4 Hot flashes — p=0.0024
N/A N=205 MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women
Hot Flashes · Menopause · Vasomotor Symptoms
Primary: Daily Frequency of Hot Flashes Per Day Assessed by Prospective Daily Diaries — 9.88; 9.66 Hot flashes/day
Phase 2 N=43 Evaluation of SAMe for Hot Flashes
Healthy, no Evidence of Disease · Hot Flashes
Primary: Percent of Baseline in Average Hot Flash Activity (Score and Frequency) — 64.6; 67.4 Percent of baseline — p=0.0903
Phase 3 N=1,831 A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
Hot Flashes
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 391; 415; 389; 106 participants
Phase 2 N=374 MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
Menopause Hot Flashes
Primary: Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12 — -1.92; -2.75; -2.75; -1.39 VMS per day
Phase 2 N=87 Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes
Hot Flashes
Primary: Change From Baseline to Week 12 in The Weekly General Hot Flash Score — -12.19; -26.51 score on a scale — p=<0.001
N/A N=8 HIRREM Hot Flashes Study
Vasomotor Symptoms · Hot Flashes · Menopause
Primary: Reduction in Hot Flash Severity Score Based on Diary Data — -0.39; -0.38 score on a scale
Phase 2 N=102 Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause
Hot Flashes
Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 8 — 82.44; 83.18; 37.3; 28.5 Hot flashes — p=0.0177
N/A N=250 A Mind-Body Intervention for Hot Flash Management
Hot Flashes · Postmenopausal Symptoms · Breast Cancer
Primary: Hot Flash Daily Diary — 88.7; 94.6; 41.3; 55.9 Hot Flash Score
N/A N=339 MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms
Hot Flashes · Menopause · Vasomotor Disturbance
Primary: Frequency of Hot Flashes (Vasomotor Symptom [VMS] Frequency) -- Week 4 — 5.3; 5.1; 5.8 number of hot flashes per day
Phase 3 N=454 Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms
Hot Flashes
Primary: Mean Change in the Number of Moderate to Severe Vasomotor Symptoms Per Day — -5.32; -6.19; -4.76; -8.44 Vasomotor symptoms per day — p=<0.0001